Nestle enters agreement to develop ulcerative colitis therapy
September 16, 2015 at 08:30 AM EDT
ZURICH, Sept 16 (Reuters) - Nestle is working with Lipid Therapeutics to develop and commercialise a new therapeutic treatment for mild-to-moderate ulcerative colitis, which can causes ulcers, bleeding and pain due to inflammation of the colon, the company said on Wednesday.
